Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion

• Status: Completed
• Trial end date: 2000-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

3-Hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) decrease apolipoprotein B-100-containing lipoproteins by increasing their fractional catabolic rates through low-density lipoproteins (LDL) receptor-mediated uptake. Their influence on hepatic secretion of these lipoproteins is controversial. The current study investigates whether simvastatin influences lipoprotein secretion.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Bonn
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Hypercholesterolemia

Exclusion Criteria:

• Obesity

• Treatment with lipid-lowering drugs